DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today that it has obtained a notice of allowance from the U.S. Patent & Trademark Office allowing its patent entitled “Immunoaffinity Isolation of Modified Peptides from Complex Mixtures” (Rush et al., U.S. Pat. No. 7,198,896). The patented technology, which CST commercializes under the trademarks PhosphoScan® and AcetylScan®, covers the selective isolation of a target population of post-translationally modified peptides from a complex mixture of peptides by using immobilized modification-specific antibodies, followed by mass spectrometric determination of modification sites and parent protein identification. The technology is uniquely applicable and has been used extensively for global phospho-profiling (PhosphoScan®) and acetylation profiling (AcetylScan®) for understanding disease mechanism, target and substrate validation and identification of drug-response biomarkers.
